How Merck uses patents to help maintain Keytruda’s exorbitant price
ICIJ’s Cancer Calculus investigation of Merck & Co.’s blockbuster drug Keytruda exposed the intricate web of patents that Merck and other pharmaceutical companies build to protect their profit margins and delay competitors from entering the market and offering potentially more affordable versions of the drug. Timeline of Merck’s active U.S. Keytruda patents Merck’s original patents…